AbbVie's Humira Patents Are Noninventive, Boehringer Says

By Nicole Narea (September 13, 2017, 1:34 PM EDT) -- Drugmaker Boehringer Ingelheim International GmbH on Monday shot back at competitor AbbVie Inc.'s suit in Delaware federal court alleging that its proposed biosimilar of the blockbuster immunosuppressant Humira runs afoul of 74 patents, arguing that the company has created a "patent thicket" of noninventive patents to prevent competition....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!